** Shares in Moderna MRNA.O rallying 12.7% on Friday, touching highest level since Sept 2024 and eyeing their biggest one-day percentage gain since early March after the drug developer hosted an investor event and showcased its pipeline

** Jefferies raised its price target for the stock to $53 from $45 while Piper Sandler upped its price target to $77 from $69

** Jefferies analyst Andrew Tsai pointed to earlier-stage programs mostly for cancer that could "meaningfully diversify" its drug pipeline including T-cell engagers for myeloma and ovarian cancer, various Phase I/II cancer antigens, a Phase II multiple sclerosis (MS) asset and studies in CAR-T for lupus (SLE). Tsai sees Phase III melanoma data expected in the second half of 2026 as "a major event for MRNA stock"

** Tsai said that in 2026, revenue could grow by 10% Y/Y, helping reduce cash burn and ensuring 2028 cash breakeven and that by 2027-28, MRNA could be marketing 7+ products across respiratory, oncology, and rare diseases

** Leerink analyst Mani Foroohar wrote that since MRNA management did not update Opex, cash guidance, there could be "heavy trimming/out-licensing of this broad pipeline as late-stage programs (including larger, more costly trials) advance."

** MRNA stock, which was leading a healthcare sector rally on Friday, last traded at $67.99 vs median PT of $45, as per LSEG, which shows 25 analyst ratings: 4 'buy,' 17 'hold,' 3 'sell' and 1 'strong sell'

** YTD shares up ~130% vs gain of 3.4% for S&P 500 healthcare sector .SPXHC, which was up 2.8% on the day